Next Article in Journal
Independent Mechanisms Lead to Genomic Instability in Hodgkin Lymphoma: Microsatellite or Chromosomal Instability
Next Article in Special Issue
Autologous Transplantation for Older Adults with AML
Previous Article in Journal
Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency
Previous Article in Special Issue
Geriatric Assessment in Older Patients with Acute Myeloid Leukemia
Review

Bridging Strategies to Allogeneic Transplant for Older AML Patients

Department of Medicine III, Hematology and Oncology, Technische Universität München, 80333 Munich, Germany
*
Author to whom correspondence should be addressed.
Judith Hecker and Isabella Miller shared first authorship.
Received: 7 May 2018 / Revised: 27 June 2018 / Accepted: 6 July 2018 / Published: 11 July 2018
(This article belongs to the Special Issue Treatment of Older Adults with Acute Myeloid Leukemia)
Treatment options for older patients with intermediate or high-risk acute myeloid leukemia (AML) remain unsatisfactory. Allogeneic stem cell transplantation, the treatment of choice for the majority of younger AML patients, has been hampered in elderly patients by higher treatment related mortality, comorbidities and lack of a suitable donor. With the higher availability of suitable donors as well as of reduced intensity conditioning regimens, novel low intensity treatments prior to transplantation and optimized supportive care, the number of older AML patients being successfully transplanted is steadily increasing. Against this background, we review current treatment strategies for older AML patients planned for allogeneic stem cell transplantation based on clinical trial data, discussing differences between approaches with advantages and pitfalls of each. We summarize pre-treatment considerations that need to be taken into account in this highly heterogeneous older population. Finally, we offer an outlook on areas of ongoing clinical research, including novel immunotherapeutic approaches that may improve access to curative therapies for a larger number of older AML patients. View Full-Text
Keywords: elderly AML; bridging strategies; allogeneic stem cell transplant; chemotherapy; hypomethylating agents elderly AML; bridging strategies; allogeneic stem cell transplant; chemotherapy; hypomethylating agents
MDPI and ACS Style

Hecker, J.; Miller, I.; Götze, K.S.; Verbeek, M. Bridging Strategies to Allogeneic Transplant for Older AML Patients. Cancers 2018, 10, 232. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10070232

AMA Style

Hecker J, Miller I, Götze KS, Verbeek M. Bridging Strategies to Allogeneic Transplant for Older AML Patients. Cancers. 2018; 10(7):232. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10070232

Chicago/Turabian Style

Hecker, Judith, Isabella Miller, Katharina S. Götze, and Mareike Verbeek. 2018. "Bridging Strategies to Allogeneic Transplant for Older AML Patients" Cancers 10, no. 7: 232. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10070232

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop